EMA Authorised: Eltrombopag Accord (eltrombopag olamine) — Accord Healthcare S.L.U.

View source ↗

Summary

The EU's EMA authorised the brand product Eltrombopag Accord (eltrombopag olamine) for treatment of immune thrombocytopenia. The marketing authorization holder …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Eltrombopag Accord (eltrombopag olamine)

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombocytopenic, Idiopathic. MAH: Accord Healthcare S.L.U.. Decision date: 10/10/2025